Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Thein KZ, et al. Among authors: karp dd. Invest New Drugs. 2022 Apr;40(2):461. doi: 10.1007/s10637-021-01192-5. Invest New Drugs. 2022. PMID: 34705134 Free PMC article. No abstract available.
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Fu S, et al. Ann Oncol. 2015 May;26(5):1012-1018. doi: 10.1093/annonc/mdv066. Epub 2015 Feb 10. Ann Oncol. 2015. PMID: 25669829 Free PMC article. Clinical Trial.
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Rodrigues HV, et al. Invest New Drugs. 2015 Jun;33(3):700-9. doi: 10.1007/s10637-015-0238-2. Epub 2015 Apr 24. Invest New Drugs. 2015. PMID: 25902899 Clinical Trial.
The mu opioid receptor: A new target for cancer therapy?
Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. Singleton PA, et al. Among authors: karp dd. Cancer. 2015 Aug 15;121(16):2681-8. doi: 10.1002/cncr.29460. Epub 2015 Jun 4. Cancer. 2015. PMID: 26043235 Free article. Review.
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. Janku F, et al. Among authors: karp dd. Oncotarget. 2015 Sep 29;6(29):26886-94. doi: 10.18632/oncotarget.4723. Oncotarget. 2015. PMID: 26330075 Free PMC article.
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Liu X, et al. BMC Cancer. 2015 Oct 16;15:713. doi: 10.1186/s12885-015-1701-3. BMC Cancer. 2015. PMID: 26474549 Free PMC article.
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JS. Al-Rohil RN, et al. Among authors: karp dd. Cancer. 2016 Jan 15;122(2):249-57. doi: 10.1002/cncr.29738. Epub 2015 Oct 19. Cancer. 2016. PMID: 26479420 Free article.
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Khawaja MR, et al. Cancer Chemother Pharmacol. 2016 May;77(5):973-7. doi: 10.1007/s00280-016-3009-7. Epub 2016 Mar 24. Cancer Chemother Pharmacol. 2016. PMID: 27014780 Free PMC article. Clinical Trial.
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Wheler JJ, et al. Cancer Res. 2016 Jul 1;76(13):3690-701. doi: 10.1158/0008-5472.CAN-15-3043. Epub 2016 May 18. Cancer Res. 2016. PMID: 27197177 Clinical Trial.
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. Janku F, et al. Among authors: karp dd. Mol Cancer Ther. 2016 Jun;15(6):1397-404. doi: 10.1158/1535-7163.MCT-15-0712. Epub 2016 May 20. Mol Cancer Ther. 2016. PMID: 27207774
171 results